Baader Bank Aktiengesellschaft Purchases 3,708 Shares of Axsome Therapeutics, Inc. $AXSM

Baader Bank Aktiengesellschaft raised its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 175.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 5,823 shares of the company’s stock after buying an additional 3,708 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Axsome Therapeutics were worth $1,062,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Allworth Financial LP boosted its position in Axsome Therapeutics by 6.6% in the 3rd quarter. Allworth Financial LP now owns 1,442 shares of the company’s stock valued at $175,000 after buying an additional 89 shares during the last quarter. Meridian Wealth Management LLC boosted its position in Axsome Therapeutics by 0.5% in the 3rd quarter. Meridian Wealth Management LLC now owns 22,124 shares of the company’s stock valued at $2,687,000 after buying an additional 103 shares during the last quarter. GAMMA Investing LLC boosted its position in Axsome Therapeutics by 65.4% in the 4th quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock valued at $49,000 after buying an additional 106 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Axsome Therapeutics by 6.1% in the 3rd quarter. PNC Financial Services Group Inc. now owns 1,856 shares of the company’s stock valued at $225,000 after buying an additional 107 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D boosted its position in Axsome Therapeutics by 0.6% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 18,158 shares of the company’s stock valued at $2,205,000 after buying an additional 109 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AXSM has been the topic of a number of recent research reports. TD Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a research report on Friday, May 1st. Royal Bank Of Canada increased their price objective on Axsome Therapeutics from $242.00 to $302.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. Wolfe Research initiated coverage on Axsome Therapeutics in a research report on Monday, February 23rd. They issued an “outperform” rating and a $230.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $272.00 price objective on shares of Axsome Therapeutics in a research report on Monday, May 4th. Finally, HC Wainwright increased their price objective on Axsome Therapeutics from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $251.26.

Insider Transactions at Axsome Therapeutics

In other news, COO Mark L. Jacobson sold 35,378 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $161.88, for a total value of $5,726,990.64. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Mark Coleman sold 25,000 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $161.11, for a total value of $4,027,750.00. Following the completion of the transaction, the director owned 47,140 shares in the company, valued at $7,594,725.40. This represents a 34.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 72,628 shares of company stock worth $12,205,662 in the last three months. Insiders own 20.60% of the company’s stock.

Axsome Therapeutics Stock Down 1.3%

NASDAQ:AXSM opened at $232.27 on Friday. Axsome Therapeutics, Inc. has a 12-month low of $96.09 and a 12-month high of $235.91. The company has a quick ratio of 1.32, a current ratio of 1.39 and a debt-to-equity ratio of 2.27. The firm has a market capitalization of $11.95 billion, a P/E ratio of -62.27 and a beta of 0.59. The stock’s fifty day simple moving average is $179.76 and its 200-day simple moving average is $168.03.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The company had revenue of $191.20 million during the quarter, compared to the consensus estimate of $191.10 million. The business’s quarterly revenue was up 57.4% on a year-over-year basis. Equities research analysts expect that Axsome Therapeutics, Inc. will post -2.14 earnings per share for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.